Published in Chin J Cancer Res on April 01, 2014
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet (1998) 8.91
Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res (2007) 3.20
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet (2012) 3.20
The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev (2003) 2.64
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2006) 2.50
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43
Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin (2011) 2.42
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res (2003) 2.27
Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst (2002) 2.16
RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res (2005) 2.11
Aurora kinases: new targets for cancer therapy. Clin Cancer Res (2006) 1.85
Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res (2004) 1.83
Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc Natl Acad Sci U S A (2002) 1.80
Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer (2001) 1.77
Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res (2007) 1.42
Identification of V23RalA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J Biol Chem (2005) 1.40
Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res (2007) 1.36
The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res (2010) 1.33
Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis (2008) 1.30
The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res (2005) 1.28
Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC). Ann Surg Oncol (2007) 1.15
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 1.12
Overexpression and amplification of STK15 in human gliomas. Int J Oncol (2004) 1.06
STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer (2004) 1.06
Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer. PLoS One (2013) 1.01
Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend. Eur J Cardiothorac Surg (2000) 0.95
Translational up-regulation of Aurora-A in EGFR-overexpressed cancer. J Cell Mol Med (2009) 0.84